A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic Characteristics of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 29 Jan 2025
At a glance
- Drugs TQC 2938 (Primary)
 - Indications Chronic obstructive pulmonary disease
 - Focus Therapeutic Use
 - Sponsors Chia Tai Tianqing Pharmaceutical Group
 
Most Recent Events
- 29 Jan 2025 New trial record